



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## MS-275 (Entinostat)

**Catalog #:** 27011

**Lot #:** 150715


**Size:** 25 mg

**Structure:**

**CAS Registry #:** 209783-80-2

**Purity:** ≥99%

**Chemical Formula:** C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>



**Molecular Weight:** 376.41

**Description:** MS-275, also known as Entinostat, is an inhibitor of histone deacetylases (HDACs) and preferentially inhibits HDAC1 over HDAC3. It does not inhibit HDAC8 (IC<sub>50</sub> > 100 μM). It induces cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1), slowing cell growth, differentiation, and tumor development *in vivo*. Recent studies suggest that MS-275 may be particularly useful as an antineoplastic agent when combined with other drugs like adriamycin, inhibitors of PARPs, or inhibitors of Hsp90.

**Appearance:** White to off-white crystalline solid

**Solubility:** Soluble in DMSO at 25 mg/ml with slight warming. MS-275 is poorly soluble in ethanol and water.

**Biological Activity:** MS-275 inhibits HDAC1 with an IC<sub>50</sub> of 300 nM and HDAC3 with an IC<sub>50</sub> value of 8 μM.

**Storage/Stability:** Store at or below -20 °C.

**Quality Control:** The purity was determined by HPLC analysis.

### References:

1. Hu., E. *et al.*, *J. Pharmacol. Exp. Ther.* 2003; **307**: 720-728.
2. Saito, A., *et al.*, *Proc. Natl. Acad. Sci. USA* 1999; **96**: 4592-4597.
3. Jaboin, J., *et al.*, *Cancer Res.* 2002; **62**: 6108-6115.
4. Xu, J. *et al.*, *Cancer Res.* 2008; **(68)16**: 6718 – 6726.
5. Gaymes, T.J., *et al.*, *Haematologica* 2009; **94**: 638-646.